Stock Track | Veracyte Soars 8% After Impressive Q3 Results, Raised Guidance Fuel Growth Optimism

Stock Track11-08

Shares of Veracyte Inc. (VCYT) soared over 8% in pre-market trading on November 8, 2024, after the molecular diagnostics company reported impressive third-quarter financial results and raised its full-year guidance, fueling optimism about its growth prospects.

For the third quarter of 2024, Veracyte's revenue surged 29% year-over-year to $115.9 million, beating analyst estimates of $109.81 million. This robust growth was driven by strong performance in the company's testing segment, with its Decipher and Afirma tests seeing revenue growth of 48% and 19%, respectively. Adjusted earnings per share of $0.20 also exceeded expectations of $0.03.

Encouraged by the strong Q3 performance, Veracyte raised its full-year 2024 revenue guidance to $442-$445 million, representing year-over-year growth of 22-23%. The company also expects its Adjusted EBITDA margin to be slightly more than 20% for the year, reflecting a focus on profitability.

Following the impressive results and raised guidance, several analysts have reacted positively, raising their price targets and reiterating buy ratings on Veracyte's stock. Analysts cited the company's robust financial performance, expanding adoption of its tests, and the anticipated launch of its Minimal Residual Disease (MRD) test for bladder cancer in the first half of 2026 as key growth drivers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1121191675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 21:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121191675","market":"us","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 8% After Impressive Q3 Results, Raised Guidance Fuel Growth Optimism","media":"Stock Track","content":"<p>Shares of Veracyte Inc. (VCYT) soared over 8% in pre-market trading on November 8, 2024, after the molecular diagnostics company reported impressive third-quarter financial results and raised its full-year guidance, fueling optimism about its growth prospects.</p>\n\n<p>For the third quarter of 2024, Veracyte's revenue surged 29% year-over-year to $115.9 million, beating analyst estimates of $109.81 million. This robust growth was driven by strong performance in the company's testing segment, with its Decipher and Afirma tests seeing revenue growth of 48% and 19%, respectively. Adjusted earnings per share of $0.20 also exceeded expectations of $0.03.</p>\n\n<p>Encouraged by the strong Q3 performance, Veracyte raised its full-year 2024 revenue guidance to $442-$445 million, representing year-over-year growth of 22-23%. The company also expects its Adjusted EBITDA margin to be slightly more than 20% for the year, reflecting a focus on profitability.</p>\n\n<p>Following the impressive results and raised guidance, several analysts have reacted positively, raising their price targets and reiterating buy ratings on Veracyte's stock. Analysts cited the company's robust financial performance, expanding adoption of its tests, and the anticipated launch of its Minimal Residual Disease (MRD) test for bladder cancer in the first half of 2026 as key growth drivers.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 8% After Impressive Q3 Results, Raised Guidance Fuel Growth Optimism</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 8% After Impressive Q3 Results, Raised Guidance Fuel Growth Optimism\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 21:03 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Veracyte Inc. (VCYT) soared over 8% in pre-market trading on November 8, 2024, after the molecular diagnostics company reported impressive third-quarter financial results and raised its full...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1121191675","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121191675","pubTimestamp":1731071033,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Veracyte Inc.  soared over 8% in pre-market trading on November 8, 2024, after the molecular diagnostics company reported impressive third-quarter financial results and raised its full-year guidance, fueling optimism about its growth prospects.For the third quarter of 2024, Veracyte's revenue surged 29% year-over-year to $115.9 million, beating analyst estimates of $109.81 million. This robust growth was driven by strong performance in the company's testing segment, with its Decipher a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"股票赛道Veracyte在令人印象深刻的第三季度业绩后飙升8%，上调指引助长了增长乐观情绪","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Shares of Veracyte Inc. (VCYT) soared over 8% in pre-market trading on November 8, 2024, after the molecular diagnostics company reported impressive third-quarter financial results and raised its full-year guidance, fueling optimism about its growth prospects.\nFor the third quarter of 2024, Veracyte's revenue surged 29% year-over-year to $115.9 million, beating analyst estimates of $109.81 million. This robust growth was driven by strong performance in the company's testing segment, with its Decipher and Afirma tests seeing revenue growth of 48% and 19%, respectively. Adjusted earnings per share of $0.20 also exceeded expectations of $0.03.\nEncouraged by the strong Q3 performance, Veracyte raised its full-year 2024 revenue guidance to $442-$445 million, representing year-over-year growth of 22-23%. The company also expects its Adjusted EBITDA margin to be slightly more than 20% for the year, reflecting a focus on profitability.\nFollowing the impressive results and raised guidance, several analysts have reacted positively, raising their price targets and reiterating buy ratings on Veracyte's stock. Analysts cited the company's robust financial performance, expanding adoption of its tests, and the anticipated launch of its Minimal Residual Disease (MRD) test for bladder cancer in the first half of 2026 as key growth drivers.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1121191675"}